Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant...
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug...
ReTo Eco-Solutions Subsidiary Showcases Equipment and Intelligent Solutions at Excon 2025 to Advance India Market Presence
BEIJING, Dec. 12, 2025 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company") today announced that its wholly owned subsidiary, Beijing REIT Equipment Technology Co., Ltd. ("REIT Equipment"), is participating in Excon...
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. The...
TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By...
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide rights, excluding...
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The...
VINSSEN and ILDO F&C Form Exclusive Alliance to Advance Composite Bipolar Plate Technology for Hydrogen Systems
Joint innovation targets lower costs, higher durability, and broader applications across the hydrogen value chain SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- VINSSEN, a maritime decarbonization technology company specializing in hydrogen fuel...
Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond
SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $10 million Seed financing...
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety...